EUVIMEDEUVIMED entdecken
Open Access

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma

Liia Akhuba, Zhanna Tigai, Dmitrii Shek

Cancer Drug Resistance · 2023 · 6 (2) · 327-331

DOI: 10.20517/cdr.2022.142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Drug Resistance, 2023. Verfasst von Liia Akhuba und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Health Sciences, Western Sydney University, Sydney, NSW 2145, Australia. Die Arbeit wurde bisher 13-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2030, pancreatic ductal adenocarcinoma (PDAC) will become the second leading cause of cancer-related mortality in the world. Unfortunately, neither conventional chemotherapy nor novel immunotherapeutic strategies can provide durable responses and the survival prognosis remains very low. PDAC is notorious for its immune-resistant features and unique genomic landscape facilitating tumor escape from immunosurveillance. Novel immune-checkpoint inhibitors (ICI) failed to show promising efficacy and other multi-modal approaches are currently being validated in multiple clinical trials. In this paper, we provide our opinion on the major mechanisms responsible for PDAC resistance to ICI therapy and provide our view on future strategies which may overcome those barriers.

Schlagwörter

Stichwörter der Autor:innen

Pancreatic cancerimmune-checkpoint inhibitorsmicroenvironmenttumor resistance

Autor:innen und Institutionen

  • School of Health Sciences, Western Sydney University, Sydney, NSW 2145, Australia.
  • Accreditation Centre, RUDN University, Moscow 117198, Russia.
  • Blacktown Clinical School, Western Sydney University, Sydney, NSW 2145, Australia.
  • Blacktown Mt Druitt Hospital, Sydney, NSW 2145, Australia.
  • Westmead Institute for Medical Research, Sydney, NSW 2145, Australia.

Zitieren

APA

Akhuba, L., Tigai, Z., & Shek, D. (2023). Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma. Cancer Drug Resistance, 6(2), 327-331. https://doi.org/10.20517/cdr.2022.142

Vancouver

Akhuba L, Tigai Z, Shek D. Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma. Cancer Drug Resistance. 2023;6(2):327-331. doi:10.20517/cdr.2022.142

BibTeX
@article{Akhuba2023,
  author = {Akhuba, Liia and Tigai, Zhanna and Shek, Dmitrii},
  title = {Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma},
  journal = {Cancer Drug Resistance},
  year = {2023},
  volume = {6},
  number = {2},
  pages = {327--331},
  doi = {10.20517/cdr.2022.142}
}
Kostenlos starten →